中国循证心血管医学杂志

参考文献

[1] Ibanez B,James S,Agewall S,et al, ESC Scientific Document Group.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J,2018,39(2):119-77.

[2] American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions. 2013ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,61(4):e78-140.

[3] Zijlstra F,Patel A,Jones M,et al. Clinical characteristics and outcome of patients with early(<2 h),intermediate(2-4 h)and late(>4 h)presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction[J]. Eur Heart J,2002,23(7):550-7.

[4]中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会,血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.

[5] Neumann FJ,Sousa-Uva M,Ahlsson A,et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165.

[6] Esposito M,Bader Y,Pedicini R,et al. The role of acute circulatory support in ST-segment elevation myocardial infarction complicated by cardiogenic shock[J]. Indian Heart J,2017,69(5):668-74.

[7] Thiele H,Akin I,Sandri M,et al, CULPRIT-SHOCK Investigators. PCI strategies in patients with acute myocardial infarction and cardiogenic shock[J]. N Engl J Med,2017,377(25):2419-32.

[8] P?ss J,K?ster J,Fuernau G,et al. Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction[J]. J Am Coll Cardiol,2017,69(15):1913-20.

[9] Awamia B,Mehran R,Qiu W,et al. Risk scores in acute coronary syndrome and percutaneous coronary intervention:a review[J]. Am Heart J,2013,165(4):441-50.

[10] McNamara RL,Kennedy KF,Cohen DJ,et al. Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction[J]. J Am Coll Cardiol,2016,68(6):626-35.

[11] Song C,Fu R,Dou K,et al. The CAMI-score:A Novel Tool derived From CAMI Registry to Predict In-hospital Death among Acute Myocardial Infarction Patients[J]. Sci Rep,2018, 8(1):9082.

[12] Granger CB,Goldberg RJ,Dabbous O,et al. Predictors of hospital mortality in the global registry of acute coronary events[J]. Arch Intern Med,2003,163(19):2345-53.

[13] Morrow DA,Antman EM,Charlesworth A,et al. TIMI risk score for ST-elevation myocardial infarction:A convenient, bedside, clinical score for risk assessment at presentation:An intravenous nPA for treatment of infarcting myocardium early II trial substudy[J]. Circulat ion,2000,102(17):2031-7.

[14] Mehran R,Pocock SJ,Nikolsky E,et al. A risk score to predict bleeding in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2010,55(23):2556-66.

[15] Desai NR,Kennedy KF,Cohen DJ,et al. Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction:The acute coronary treatment and intervention outcomes network(ACTION)registry?-Get With The Guidelines(GWTG)[J].Am Heart J,2017,194(0):16-24.

[16] Simonsson M,Winell H,Olsson H,et al. Development and Validation of a Novel Risk Score for In-Hospital Major Bleeding in Acute Myocardial Infarction:The SWEDEHEART Score[J]. J Am Heart Assoc,2019,8(5):e012157.

[17] Cahill TJ,Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention:Mechanisms,incidence and identification of patients at risk[J]. World J Cardiol,2017,9(5):407-15.

[18] Santoro GM,Carrabba N,Migliorini A,et al. Acute heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention[J]. Eur J Heart Fail,2008,10(8):780-5.

[19] Kelly DJ,Gershlick T,Witzenbichler B,et al. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction:the HORIZONS-AMI trial[J]. Am Heart J,2011,162(4):663-70.

[20] Wessler JD,Généreux P,Mehran R,et al. Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes? A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials[J]. JACC Cardiovasc Interv,2016,9(4):331-7.

[21] Planer D,Mehran R,Witzenbichler B,et al. Prognostic utility of left ventricular end-diastolic pressure in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Am J Cardiol,2011,108:1068-74.

[22] Hung CL,Verma A,Uno H,et al. Longitudinal and circumferential strain rate, left ventricular remodeling,and prognosis after myocardial infarction[J]. J Am Coll Cardiol,2010,56(22):1812-22.

[23] Eitel I,de Waha S,W?hrle J,et al. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol,2014,64(12):1217-26.

[24] Wollenweber T,Roentgen P,Sch?fer A,et al. Characterizing the inflammatory tissue response to acute myocardial infarction by clinical multimodality noninvasive imaging[J]. Circ Cardiovasc Imaging,2014,7(5):811-8.

[25] Seropian IM,Sonnino C,Van Tassell BW,et al. Inflammatory markers in ST-elevation acute myocardial infarction[J]. Eur Heart J Acute Cardiovasc Care,2016,5(4):382-95.

[26] Yancy CW,Jessup M,Bozkurt B,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation,2017,136(6):e137-e161.

[27] Fox KA,Dabbous OH,Goldberg RJ,et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome:prospective multinationa observational study(GRACE)[J]. BMJ,2006,333(7578):1091.

[28] Eagle KA,Lim MJ,Dabbous OH,et al. A validated prediction model for all forms of acute coronary syndrome:estimating the risk of6-month postdischarge death in an international registry[J]. JAMA,2004,291(22):2727-33.

[29] Fox KAA,Fitzgerald G,Puymirat E,et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score[J]. BMJ Open,2014,4(2):e004425.(www.outcomes.org/grace)

[30] Fox KA,Carruthers KF,Dunbar DR,et al. Underestimated and underrecognized:the late consequences of acute coronary syndrome(GRACE UK-Belgian Study)[J]. Eur Heart J,2010,31(22):2755-64.

[31] Abu-Assi E,García-Acu?a JM,Pe?a-Gil C,et al. Validation of the GRACE risk score for predicting death within 6 months of follow-up in a contemporary cohort of patients with acute coronary syndrome[J].Rev Esp Cardiol,2010,63(6):640-8.

[32]黄德嘉,霍勇,张澍,等.代表中华医学会心血管病学分会,中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会心血管冠状动脉及电生理介入治疗专家工作组.冠心病血运重建后心脏性猝死的预防[J].中华心律失常学杂志,2017,21(1):9-21.

[33] Brignole M,Moya A,de Lange FJ,et al. ESC Scientific Document Group. 2018 ESC Guidelines for the diagnosis and management of syncope[J]. Eur Heart J,2018,39(21):1883-948.

[34] Sianos G,Morel MA,Kappetein AP,et al. The SYNTAX Score:an angiographic tool grading the complexity of coronary artery disease[J].EuroIntervention,2005,1(2):219-27.

[35] Farooq V,van Klaveren D,Steyerberg EW,et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients:development and validation of SYNTAX score II[J]. Lancet,2013,381(9867):639-50.

[36] Nashef SA,Roques F,Sharples LD,et al. EuroSCORE II[J]. Eur J Cardiothorac Surg,2012,41(4):734-44.

[37] Shahian DM,O'Brien SM,Filardo G,et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models:part 1--coronary artery bypass grafting surgery[J]. Ann Thorac Surg,2009,88(1 Suppl):S2-22.

[38] Ad N,Holmes SD,Patel J,et al. Comparison of EuroSCORE II, Original EuroSCORE, and The Society of Thoracic Surgeons Risk Score in Cardiac Surgery Patients[J]. Ann Thorac Surg,2016,102(2):573-9.

[39]中国医师协会心血管内科医师分会血栓防治专业委员会,中华医学会心血管病学分会介入学组,中华心血管病杂志编辑委员会.替格瑞洛临床应用中国专家共识[J].中华心血管病杂志,2016,44(2):112-20.

[40] Costa F,van Klaveren D,James S,et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISEDAPT)score:a pooled analysis of individual-patient datasets from clinical trials[J]. Lancet,2017,389(10073):1025-34.

[41] Yeh RW,Secemsky EA,Kereiakes DJ,et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention[J]. JAMA,2016,315(16):1735-49.

[42] Watanabe H,Domei T,Morimoto T,et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI:The STOPDAPT-2 Randomized Clinical Trial[J]. JAMA,2019,321(24):2414-27.

[43] Hahn JY,Song YB,Oh JH,et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention:The SMARTCHOICE Randomized Clinical Trial[J]. JAMA,2019,321(24):2428-37.

[44] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-77.

[45] Lip GYH,Banerjee A,Boriani G,et al. Antithrombotic Therapy for Atrial Fibrillation:CHEST Guideline and Expert Panel Report[J].Chest,2018,154(5):1121-201.

[46] Lopes RD,Heizer G,Aronson R,et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation[J]. N Engl J Med,2019,380(16):1509-24.

[47] Lip GYH,Collet JP,Haude M,et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions:a joint consensus document of the European Heart Rhythm Association(EHRA),European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions(EAPCI),and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS),AsiaPacific Heart Rhythm Society(APHRS),Latin America Heart Rhythm Society(LAHRS),and Cardiac Arrhythmia Society of Southern Africa(CASSA)[J]. Europace,2019,21(2):192-3.

[48] Lip GY,Nieuwlaat R,Pisters R,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach:the euro heart survey on atrial fibrillation[J]. Chest,2010,137(2):263-72.

[49] Pisters R,Lane DA,Nieuwlaat R,et al. A novel user-friendly score(HASBLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey[J]. Chest,2010,138(5):1093-100.

[50] van Rein N,Heide-J?rgensen U,Lijfering WM,et al. Major Bleeding Rates in Atrial Fibrillation Patients on Single,Dual,or Triple Antithrombotic Therapy[J]. Circulation,2019,139(6):775-86.

[51] Grundy SM,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2019,73(24):e285-e350.

[52] Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. European Heart Journal,2020,41(1):111-88.